Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Next Previous
Trial Profile

A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms CLARITY EXT; CLARITY EXTENSION
  • Sponsors EMD Serono

    • Most Recent Events

    • 12 Sep 2019 Results of a post-hoc analysis in patients enrolled in CLARITY and CLARITY Extension studies published in the Merck media release
    • 28 Aug 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).
    • 01 Jul 2019 Results assessing impact of non randomized droup out on treatment switching adjustment using CLARITY and CLARITY Extension trial published in the Value in Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top